DE602004021367D1 - Verfahren zur beurteilung des phänotyps eines patienten mit morbus crohn über eine serologische i2-, ompc- und asca-reaktion - Google Patents

Verfahren zur beurteilung des phänotyps eines patienten mit morbus crohn über eine serologische i2-, ompc- und asca-reaktion

Info

Publication number
DE602004021367D1
DE602004021367D1 DE602004021367T DE602004021367T DE602004021367D1 DE 602004021367 D1 DE602004021367 D1 DE 602004021367D1 DE 602004021367 T DE602004021367 T DE 602004021367T DE 602004021367 T DE602004021367 T DE 602004021367T DE 602004021367 D1 DE602004021367 D1 DE 602004021367D1
Authority
DE
Germany
Prior art keywords
crohn
antibodies
subtype
disease
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602004021367T
Other languages
English (en)
Inventor
Stephan R Targan
Eric A Vasiliauskas
William S Mow
Huiying Yang
Phillip R Fleshner
Jerome I Rotter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cedars Sinai Medical Center
Original Assignee
Cedars Sinai Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cedars Sinai Medical Center filed Critical Cedars Sinai Medical Center
Priority claimed from PCT/US2004/011227 external-priority patent/WO2004091372A2/en
Publication of DE602004021367D1 publication Critical patent/DE602004021367D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/686—Anti-idiotype
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DE602004021367T 2003-04-11 2004-04-09 Verfahren zur beurteilung des phänotyps eines patienten mit morbus crohn über eine serologische i2-, ompc- und asca-reaktion Expired - Lifetime DE602004021367D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/413,501 US7662569B2 (en) 2003-04-11 2003-04-11 Methods of assessing Crohn's disease patient phenotype by I2 serologic response
US10/723,164 US20050054021A1 (en) 2003-04-11 2003-11-26 Methods of assessing Crohn's disease patient phenotype by I2, OmpC and ASCA serologic response
PCT/US2004/011227 WO2004091372A2 (en) 2003-04-11 2004-04-09 Methods of assessing crohn’s disease patient phenotype by i2, ompc and asca serologic response

Publications (1)

Publication Number Publication Date
DE602004021367D1 true DE602004021367D1 (de) 2009-07-16

Family

ID=33131415

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004021367T Expired - Lifetime DE602004021367D1 (de) 2003-04-11 2004-04-09 Verfahren zur beurteilung des phänotyps eines patienten mit morbus crohn über eine serologische i2-, ompc- und asca-reaktion

Country Status (4)

Country Link
US (4) US7662569B2 (de)
AT (1) ATE433113T1 (de)
DE (1) DE602004021367D1 (de)
IL (1) IL171020A (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7662569B2 (en) * 2003-04-11 2010-02-16 Cedars-Sinai Medical Center Methods of assessing Crohn's disease patient phenotype by I2 serologic response
WO2005115135A2 (en) * 2004-04-09 2005-12-08 The Regents Of The University Of California Mouse model of crohn’s disease and a method to develop specific therapeutics
US20060154276A1 (en) * 2004-05-13 2006-07-13 Prometheus Laboratories Inc. Methods of diagnosing inflammatory bowel disease
US20100021455A1 (en) * 2004-12-08 2010-01-28 Cedars-Sinai Medical Center Methods for diagnosis and treatment of crohn's disease
US12110555B2 (en) 2004-12-08 2024-10-08 Cedars-Sinai Medical Center Diagnosis and treatment of inflammatory bowel disease
US11268149B2 (en) 2004-12-08 2022-03-08 Cedars-Sinai Medical Center Diagnosis and treatment of inflammatory bowel disease
US10544459B2 (en) 2004-12-08 2020-01-28 Cedars-Sinai Medical Center Methods of using genetic variants for the diagnosis and treatment of inflammatory bowel disease
WO2008101133A2 (en) * 2007-02-14 2008-08-21 Cedars-Sinai Medical Center Methods of using genes and genetic variants to predict or diagnose inflammatory bowel disease
US7873479B2 (en) 2005-12-01 2011-01-18 Prometheus Laboratories Inc. Methods of diagnosing inflammatory bowel disease
US20100190162A1 (en) * 2007-02-26 2010-07-29 Cedars-Sinai Medical Center Methods of using single nucleotide polymorphisms in the tl1a gene to predict or diagnose inflammatory bowel disease
WO2010039931A2 (en) * 2008-10-01 2010-04-08 Cedars-Sinai Medical Center Methods of using il17rd and il23-il17 pathway genes to diagnose crohn's disease
US20100015156A1 (en) * 2007-03-06 2010-01-21 Cedars-Sinai Medical Center Diagnosis of inflammatory bowel disease in children
US8685741B1 (en) 2007-03-07 2014-04-01 Nestec S.A. Methods for diagnosing irritable bowel syndrome
US8486640B2 (en) 2007-03-21 2013-07-16 Cedars-Sinai Medical Center Ileal pouch-anal anastomosis (IPAA) factors in the treatment of inflammatory bowel disease
WO2008134569A2 (en) * 2007-04-26 2008-11-06 Cedars-Sinai Medical Center Diagnosis and treatment of inflammatory bowel disease in the puerto rican population
US20100144903A1 (en) * 2007-05-04 2010-06-10 Cedars-Sinai Medical Center Methods of diagnosis and treatment of crohn's disease
WO2011088237A1 (en) * 2010-01-13 2011-07-21 Cedars-Sinai Medical Center Methods of using znf365 genetic variants to diagnose crohn's disease
US20110189685A1 (en) * 2008-10-22 2011-08-04 Cedars-Sinai Medical Center Methods of using jak3 genetic variants to diagnose and predict crohn's disease
AU2009314259B2 (en) * 2008-11-11 2015-06-11 Nestec S.A. Methods for prediction of inflammatory bowel disease (IBD) using serologic markers
WO2010062960A2 (en) 2008-11-26 2010-06-03 Cedars-Sinai Medical Center METHODS OF DETERMINING RESPONSIVENESS TO ANTI-TNFα THERAPY IN INFLAMMATORY BOWEL DISEASE
US9580752B2 (en) 2008-12-24 2017-02-28 Cedars-Sinai Medical Center Methods of predicting medically refractive ulcerative colitis (MR-UC) requiring colectomy
WO2010120814A1 (en) 2009-04-14 2010-10-21 Prometheus Laboratories Inc. Inflammatory bowel disease prognostics
EP2494352B1 (de) 2009-10-26 2020-04-08 Prometheus Biosciences, Inc. Tests für den nachweis von anti-tnf-wirkstoffen und autoantikörpern
WO2011060098A1 (en) 2009-11-10 2011-05-19 Prometheus Laboratories Inc. Methods for predicting post-surgery risk associated with ileal pouch-anal anastomosis
SG189391A1 (en) * 2010-10-18 2013-05-31 Nestec Sa Methods for determining anti-drug antibody isotypes
CN103502815B (zh) 2011-02-17 2015-09-23 雀巢产品技术援助有限公司 检测针对抗-TNFα药物的自身抗体的测定法
EP3330711A1 (de) * 2011-03-25 2018-06-06 Cedars-Sinai Medical Center Verfahren zur diagnose und behandlung intestinaler granulome und niedriger knochendichte bei entzündlichen darmerkrankungen
WO2012154987A1 (en) 2011-05-10 2012-11-15 Nestec Sa Methods of disease activity profiling for personalized therapy management
RU2013158256A (ru) 2011-07-06 2015-07-10 Нестек С.А. АНАЛИЗЫ ДЛЯ ОБНАРУЖЕНИЯ НЕЙТРАЛИЗУЮЩИХ АУТОАНТИТЕЛ ДЛЯ БИОЛОГИЧЕСКОЙ ТЕРАПИИ TNFα
WO2013059732A1 (en) 2011-10-21 2013-04-25 Nestec S.A. Methods for improving inflammatory bowel disease diagnosis
CN103175971B (zh) * 2013-02-28 2016-10-05 苏州和锐医药科技有限公司 一种IgA抗体检测试剂盒
KR102343212B1 (ko) 2013-03-27 2021-12-23 세다르스-신나이 메디칼 센터 Tl1a 기능 및 관련된 신호전달 경로의 저해에 의한 섬유증 및 염증의 완화 및 반전
US10316083B2 (en) 2013-07-19 2019-06-11 Cedars-Sinai Medical Center Signature of TL1A (TNFSF15) signaling pathway
EP3227683B1 (de) 2014-12-05 2019-04-24 Nestec S.A. Homogene indirekte mobilitätsverschiebungstests zum nachweis von biologischen stoffen in patientenproben
JP7082945B2 (ja) 2016-03-17 2022-06-09 シーダーズ―シナイ メディカル センター Ｒｎａｓｅｔ２により炎症性腸疾患を診断する方法
GB201717301D0 (en) * 2017-10-20 2017-12-06 Nordic Bioscience As Type xvi collagen assay

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830675A (en) * 1993-03-10 1998-11-03 Cedars-Sinai Medical Center Methods for selectively detecting perinuclear anti-neutrophil cytoplasmic antibody of ulcerative colitis, primary sclerosing cholangitis, or type 1 autoimmune hepatitis
EP0615129B1 (de) * 1993-03-10 2000-05-31 Cedars-Sinai Medical Center Verfahren zum selektiven Nachweis von perinuklearen anti-neutrophilen cytoplasmischen Antikörpern bei ulzerativen Kolitis oder primärer sclerotischer Cholangitis
US5691151A (en) * 1994-10-07 1997-11-25 Regents Of University Of California Methods of screening for ulcerative colitis and crohn's disease by detecting VH3-15 autoantibody and panca
AU2438397A (en) * 1996-04-12 1997-11-07 Cedars-Sinai Medical Center Methods of determining the risk of pouchitis development
US6074835A (en) * 1996-04-12 2000-06-13 Regents Of The Univ. Of California Diagnosis, prevention and treatment of ulcerative colitis, and clinical subtypes thereof, using histone H1
US5874233A (en) * 1996-04-12 1999-02-23 Cedars-Sinai Medical Center Methods of diagnosing a clinical subtype of Crohn's disease with features of ulcerative colitis
US5916748A (en) * 1996-04-12 1999-06-29 Cedars-Sinai Medical Center Method of diagnosing a clinical subtype of crohn's disease with features of ulcerative colitis
US5968741A (en) * 1997-04-11 1999-10-19 Cedars-Sinai Medical Center Methods of diagnosing a medically resistant clinical subtype of ulcerative colitis
US6309643B1 (en) 1999-04-30 2001-10-30 The Regents Of The University Of California IBD-associated microbial antigens and methods of using same
US7138237B1 (en) 2000-05-19 2006-11-21 Cedars-Sinai Medical Center Diagnosis, prevention and treatment of Crohn's disease using the OmpC antigen
US20040053263A1 (en) * 2002-08-30 2004-03-18 Abreu Maria T. Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease
US7662569B2 (en) * 2003-04-11 2010-02-16 Cedars-Sinai Medical Center Methods of assessing Crohn's disease patient phenotype by I2 serologic response

Also Published As

Publication number Publication date
US20050054021A1 (en) 2005-03-10
US20120208212A1 (en) 2012-08-16
US8163501B2 (en) 2012-04-24
IL171020A (en) 2010-11-30
US7662569B2 (en) 2010-02-16
ATE433113T1 (de) 2009-06-15
US20100240077A1 (en) 2010-09-23
US20040203076A1 (en) 2004-10-14

Similar Documents

Publication Publication Date Title
DE602004021367D1 (de) Verfahren zur beurteilung des phänotyps eines patienten mit morbus crohn über eine serologische i2-, ompc- und asca-reaktion
DE602005022924D1 (de) Verfahren zur diagnose von morbus crohn
NZ595471A (en) Inflammatory bowel disease prognostics
ATE395596T1 (de) Diagnostisches panel ibd-first chek fur entzundliche darmerkrankung (ibd) und reizkolon
ATE462710T1 (de) Mutationen in nod2 sind bei patienten mit morbus crohn mit fibrostenosebildung assoziiert
BR0209982A (pt) Sistema e método para facilitar diagnósticos de sistema de soldagem
WO2004048600A3 (en) Diagnostic tests and methods for diagnosing inflammatory bowel disease
DE60228557D1 (de) Candida-nachweis
ATE420360T1 (de) Verfahren zur unterscheidung von morbus crohn von ulzerativer colitis und anderen magen-darm- erkrankungen durch nachweis des vorhandenseins von fäkalen antikörpern gegen saccharomyces cerevisiae
DE60116889D1 (de) Test zum direkten nachweis eines inflammatorischen anzeiger in einer körperflüssigkeitsprobe
EP2270034A3 (de) Mittel und Methoden zur Diagnose von Stress
DE50104561D1 (de) Verfahren zur Diagnose von Sepsis unter Bestimmung löslicher Cytokeratinfragmente
CA3056911A1 (en) Methods for diagnosing and treating inflammatory bowel disease
WO2022190036A3 (en) Methods for predicting treatment response in ulcerative colitis
WO2004091372A3 (en) Methods of assessing crohn’s disease patient phenotype by i2, ompc and asca serologic response
EP2008103A4 (de) Detektion von zirkulierenden endothelzellen
FI20012603A (fi) Diagnostinen menetelmä
CN217180871U (zh) 固定深度水质现场采样与监测设备
EP2505662A4 (de) Verfahren und vorrichtung zur vorhersage der pharmakologischen wirksamkeit eines wirkstoffs auf einem anti-tnf-antikörper zur behandlung von rheumatoider arthritis
Jantti et al. Prediction of 20-year outcome at onset of seropositive rheumatoid arthritis
DE60038557D1 (en) Assay
DE602006021567D1 (de) System zum abwurf von meeressonden
ATE538128T1 (de) Verfahren zur unterscheidung von colitis ulcerosa von morbus crohn durch nachweis des vorliegens von fäkalen anti-neutrophilen cytoplasmatischen antikörpern (anca)
DK2095126T3 (da) Fremgangsmåde til påvisning af humant parvovirusantigen
Kim et al. Evaluation of COVID-19 Biokit IgG/IgM clinical effectiveness in COVID-19 vaccinated individuals

Legal Events

Date Code Title Description
8364 No opposition during term of opposition